Original Source(s)
Related Content
ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer
Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.
July 1, 2026
-
1 min
Former Smokers May Merit Later Screening
Cohort data suggest past-eligible former smokers retain competing mortality profiles similar to younger current-eligible smokers
May 5, 2026
-
5 min
Is Accelerated Aging Tied to Early-Onset Carcinogenesis?
Researchers found larger biological age gaps in more recent birth cohorts and observed associations with higher risk of several cancers diagnosed before age 55.
June 26, 2026
-
4 min